Radiofrequency Ablation Devices Market: Size, Segments and Leading Players

The radiofrequency ablation devices market was valued at USD 4.3 billion in 2022. It is estimated at USD 6.7 billion in 2026 and projected to reach USD 10.5 billion by 2030, growing at a CAGR of 11.9% from 2023 to 2030, according to Grand View Research. North America led in 2022 with a 31.2% revenue share. Demand is driven by chronic and cardiovascular disease and by the shift toward minimally invasive procedures.

Radiofrequency Ablation Devices Market Size and Growth

The radiofrequency ablation devices market added roughly USD 2.4 billion between its 2022 base and the 2026 estimate. The forecast adds about USD 3.8 billion more by 2030. By our own calculation, annual growth between 2022 and 2026 is roughly 11.7%, and the 2026 to 2030 run-rate is about 11.9%. In other words, the forecast describes steady compounding rather than a sudden surge.

The figures in this article draw on Grand View Research’s market analysis. Continue your research with their Prism AI tool for more data and insights.

Three demand forces sit behind these numbers.

Disease burden. The CDC projects that atrial fibrillation will affect 12 million people in the U.S. by 2050 and 17.9 million in Europe by 2060. Arthritis adds to the chronic pain caseload: about 58.5 million U.S. adults have been diagnosed, and an estimated 78.4 million (26%) are expected to be by 2040.

Ageing populations. The WHO expects the world’s population aged 60 and above to reach 2 billion by 2050, up from 900 million in 2015. This group has the highest need for effective, low-risk treatment.

Rising healthcare spending. U.S. Census Bureau projections put global healthcare spending at USD 18.28 trillion by 2040, a CAGR of 2.6%. Germany already spends 12.8% of its GDP on healthcare, the UK 11.9% and Sweden 11.3%, which sustains procedure volumes and device purchasing.

Radiofrequency ablation also fits the economics of minimally invasive care. It treats small cancers effectively, can be repeated if new tumors appear, and shortens recovery compared with open surgery.

Download a free sample report or claim your copy of this full market intelligence report

Key Radiofrequency Ablation Devices Market Segments

The report divides the market by component type, application, end use and region. Each cut shows a different driver.

By Component Type

Disposable equipment is the largest component, with a 42.7% share in 2022. It is also the fastest-growing, with a projected CAGR of 12.2% from 2023 to 2030. The other two categories are capital equipment and reusable equipment. Disposables such as probes and electrodes are consumed with every procedure, so revenue follows procedure volume rather than one-off equipment purchases. That makes the segment the steadiest earner in the radiofrequency ablation devices market. Disposables also benefit from technology that creates controlled zones of coagulative necrosis with a lower risk of complications.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs

By Application

Surgical oncology held the largest share in 2022. Radiofrequency ablation can treat unresectable and refractory tumors, and it suits patients with multiple tumors who cannot have open surgery. The IARC counted 19.6 million new cancer diagnoses worldwide in 2020, led by breast cancer (2.3 million), lung cancer (2.2 million) and colorectal cancer (1.9 million).

The cardiology and cardiac rhythm management segment is expected to grow fastest. Atrial fibrillation is the most common arrhythmia, and catheter ablation is expected to be among the most frequently performed electrophysiological procedures. The remaining applications are pain management, gynecology and cosmetology.

By End Use

Hospitals accounted for 46.3% of the market in 2022 because of favorable reimbursement and suitable infrastructure. That leaves more than half of the market outside hospitals, in ambulatory surgery centers and research laboratories. Ambulatory surgery centers appeal because they offer lower costs, quicker recovery and higher patient satisfaction. Research laboratories are expected to grow at 11.9%, in line with the overall market, as they test safety and efficacy across oncology, cardiac, pain and dermatology uses.

By Region

North America’s 31.2% share in 2022 reflects high cancer prevalence, strong purchasing power and government support for quality care. Canada alone recorded 274,364 cancer diagnoses in 2020. Asia Pacific is expected to grow fastest at a 12.1% CAGR, helped by rising incomes, better healthcare infrastructure and multi-needle electrode technology in China and India. The ACC notes that over half of global cardiovascular deaths occur in the region, and annual CVD deaths there rose from 5.6 million in 1990 to 10.8 million in 2019.

Key Industry Players in the Radiofrequency Ablation Devices Market

The major participants are Boston Scientific Corporation, Medtronic, Stryker, Abbott, Smith & Nephew, Johnson & Johnson Services, Inc. and AngioDynamics. Their strategies fall into two patterns: acquiring technology to broaden portfolios, and launching products that make procedures more precise.

Boston Scientific bought Cosman Medical, an RF ablation systems maker, in July 2017, which widened its portfolio. In June 2020 it launched DIRECTSENSE Technology to monitor radiofrequency effects during cardiac ablation, after FDA approval in April 2020. Medtronic launched the OsteoCool RF Ablation system in Canada in April 2017 for bone metastases, and Accurian RF ablation in February 2019, with chip-enhanced probes and downloadable procedure reports. AngioDynamics acquired the BioSentry Tract Sealant System and RadiaDyne’s OARtrac radiation dose monitoring platform in September 2018 to build a continuum of care in oncology.

The pattern is that leading companies are moving beyond the ablation probe itself. They are adding monitoring, data capture and adjacent oncology or pain technologies, so competition now centers on the whole procedure rather than a single device.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Why the Radiofrequency Ablation Devices Market Outlook Is Strong

The market’s growth has several supports at once. Disease prevalence is rising, populations are ageing, and healthcare budgets are expanding. Disposables give recurring revenue, Asia Pacific offers the fastest regional expansion, and cardiology is the fastest-growing application. For investors, suppliers and content publishers tracking this space, the radiofrequency ablation devices market is a growth story built on structural demand rather than a single product cycle.

Check Out Our Dedicated Business Offerings –

U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today